Topotecan-induced Sweet's syndrome: A case report.

Area of Science:

• Dermatology
• Oncology
• Pharmacology

Background:

• Sweet's syndrome, also known as acute febrile neutrophilic dermatosis, is an inflammatory condition.
• Topotecan is a chemotherapy agent used in the treatment of various cancers.
• Drug-induced Sweet's syndrome is a recognized but uncommon adverse reaction to certain medications.

Purpose of the Study:

• To review a case of Sweet's syndrome potentially induced by topotecan chemotherapy.
• To compare the clinical presentation and diagnostic criteria of this case with established criteria for drug-induced Sweet's syndrome.
• To discuss the management and outcome of this adverse event.

Main Methods:

• Case report review.
• Comparison of clinical findings with established diagnostic criteria for drug-induced Sweet's syndrome.
• Analysis of treatment response.

Main Results:

• A patient developed Sweet's syndrome during topotecan chemotherapy.
• The case exhibited major and minor criteria consistent with drug-induced Sweet's syndrome.
• The patient showed a positive response to systemic corticosteroid therapy.

Conclusions:

• Topotecan chemotherapy can be a potential cause of Sweet's syndrome.
• Early recognition and appropriate management, including steroid therapy, are crucial for favorable outcomes in drug-induced Sweet's syndrome.
• This case underscores the importance of considering chemotherapy-induced dermatological adverse events.